1. A higher sustained complete remission rate was shown with rituximab treatment compared to mycophenolate mofetil in patients with pemphigus vulgaris.
2. Patients treated with rituximab showed a larger reduction in glucocorticoid use but had more serious adverse events compared to patients treated with mycophenolate mofetil.
Evidence Rating Level: 1 (Excellent)
1. A significantly greater proportion of patients in the voclosporin group achieved complete renal responses after 52 weeks compared to the placebo group.
2. The safety profile between the voclosporin group and placebo group were comparable with 21% of patients in both groups experiencing serious adverse events.
Evidence Rating Level: 1...